Market Capitalization (Millions $) |
179 |
Shares
Outstanding (Millions) |
101 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-126 |
Cash Flow (TTM) (Millions $) |
21 |
Capital Exp. (TTM) (Millions $) |
1 |
Adverum Biotechnologies Inc
Adverum Biotechnologies Inc is a clinical-stage gene therapy company that focuses on developing novel treatments to treat serious ocular diseases. The company's primary objective is to use gene therapy to provide long-term solutions for patients suffering from conditions such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Adverum aims to deliver its therapies using its proprietary vector platform, which is designed to efficiently and effectively deliver therapeutic genes to the eye. The company is actively engaged in clinical trials and continues to advance its pipeline of potential gene therapies to address unmet medical needs in the field of ophthalmology.
Company Address: 100 Cardinal Way Redwood City 94063 CA
Company Phone Number: 656-9323 Stock Exchange / Ticker: NASDAQ ADVM
ADVM is expected to report next financial results on March 29, 2024. |
|
|